Atco Pharma International (Pvt) Ltd
Private pharmaceutical company / importer · Karachi · Pakistan
Karachi pharmaceutical entity represented in DRAP PharmaPrice as a licensed source for oncology, vaccine and other imported or marketed pharmaceutical products.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Atco Pharma International (Pvt.) Ltd.
- Company type
- Private pharmaceutical company / importer
- Address
- B-18, S.I.T.E., Karachi, Pakistan
- Phone
- +92 21 111111645
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 63%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Adrim | Doxorubicin | 50 mg/25 mL | Injection | 1 vial | 044869 | PKR 3,485.93 | PKR 3,485.93/vial/unit | 37% above median |
| Adrim | Doxorubicin | 50 MG | Injection | 1 vial | 044869 | PKR 3,485.93 | PKR 3,485.93/vial/unit | 32% above median |
| AgB | HbsAg SURFACE ANTIGEN | 20 mcg | Vaccine | 1vial | 041166 | PKR 457.51 | PKR 457.51/vial/unit | No comparator |
| AgB | Hepatitis B vaccine (recombinant HBsAg) | 10 mcg/0.5 mL | Vaccine injection | 1 vial | 041167 | PKR 281.55 | PKR 281.55/vial/unit | No comparator |
| AgB | HbsAg SURFACE ANTIGEN | 10 MCG | Vaccine | 1 vial | 041167 | PKR 281.55 | PKR 281.55/vial/unit | No comparator |
| Daxotel | Docetaxel | 80 mg/4 mL | Injection | 4ml x 1's | 090528 | PKR 31,598.91 | PKR 7,899.73/mL | No comparator |
| Daxotel | Docetaxel | 160 mg/8 mL | Injection | 8ml x 1's | 090529 | PKR 64,716.02 | PKR 8,089.50/mL | No comparator |
| Daxotel | Docetaxel | 120 mg/6 mL | Injection | 6ml x 1's | 090530 | PKR 51,773.98 | PKR 8,629.00/mL | No comparator |
| Daxotel | Docetaxel | 20 mg/mL | Concentrate for solution for infusion | 1's | 110514 | PKR 12,826.25 | PKR 12,826.25/vial/unit | 15% below median |
| Daxotel | Docetaxel | 20 mg | Injection | 1's | 110514 | PKR 12,826.25 | PKR 12,826.25/vial/unit | Near median |
| FIVOFLU | Fluorouracil (5-FU) | 500 mg (50 mg/mL) | Injection | 1's | 045755 | PKR 147.73 | PKR 147.73/vial/unit | No comparator |
| FIVOFLU | Fluorouracil (5-FU) | 50 mg/mL | Injection | 5's | 045755 | PKR 738.63 | PKR 147.73/vial/unit | 60% above median |
| FIVOFLU | Fluorouracil (5-FU) | 250 mg/5 mL (50 mg/mL) | Injection | 1's | 045756 | PKR 92.33 | PKR 92.33/vial/unit | No comparator |
| FIVOFLU | Fluorouracil (5-FU) | 50 mg/mL | Injection | 5's | 045756 | PKR 461.65 | PKR 92.33/vial/unit | 37% below median |
| FYTOSID | Etoposide | 100 mg | Injection | vial | 044868 | PKR 1,459.23 | PKR 1,459.23/vial/unit | 57% above median |
| Gemita | Gemcitabine | 200 mg | Lyophilized powder for injection | 1 vial | 053859 | PKR 3,410.60 | PKR 3,410.60/vial/unit | 11% below median |
| Gemita | Gemcitabine | 1 g | Lyophilized powder for injection | 1 vial | 053860 | PKR 16,961.44 | PKR 16,961.44/vial/unit | 19% above median |
| Kemocarb | Carboplatin | 150 mg/15 mL | Injection | 15 ml vial | 045753 | PKR 4,530.51 | PKR 302.03/mL | Near median |
| Kemocarb | Carboplatin | 450 mg/45 mL | Injection | 45 ml vial | 045754 | PKR 12,851.61 | PKR 285.59/mL | No comparator |
| KEMOPLAT | Cisplatin | 10 mg/20 mL | Injection | 20 ml vial | 045748 | PKR 784.80 | PKR 39.24/mL | No comparator |
| KEMOPLAT | Cisplatin | 50 mg/100 mL | Injection | 100ml vial | 045749 | PKR 2,539.06 | PKR 25.39/mL | No comparator |
| Nanoxel | Paclitaxel | 30 mg | Injection | 1 vial | 052262 | PKR 6,122.40 | PKR 6,122.40/vial/unit | Near median |
| Nanoxel | Paclitaxel (albumin-bound nanoparticles) | 30 MG | Injection | 1 vial | 052262 | PKR 6,122.40 | PKR 6,122.40/vial/unit | Near median |
| Nanoxel | Paclitaxel | 100 mg | Injection | 1 vial | 052264 | PKR 25,239.01 | PKR 25,239.01/vial/unit | 30% below median |
| Nanoxel | Paclitaxel (albumin-bound nanoparticles) | 100 MG | Injection | 1 vial | 052264 | PKR 25,239.01 | PKR 25,239.01/vial/unit | 6% below median |
| Nanoxel | Paclitaxel | 300 mg | Injection | 1 vial | 052266 | PKR 57,214.91 | PKR 57,214.91/vial/unit | 45% above median |
| Nanoxel | Paclitaxel (albumin-bound nanoparticles) | 300 MG | Injection | 1 vial | 052266 | PKR 57,214.91 | PKR 57,214.91/vial/unit | 49% above median |
| NEUMOCORT | Budesonide | 200 mcg | Metered-dose inhaler | 150 doses | 059036 | PKR 293.61 | PKR 1.96/dose | Near median |
| NEUMOCORT FORTE | Budesonide | 400 mcg | Metered-dose inhaler | 150 doses | 059037 | PKR 466.31 | PKR 3.11/dose | Near median |
| NEUMOCORT FORTE METERD-DOSE INHALER | Budesonide | 400 mcg | Metered-dose inhaler | 200 doses | 059037 | PKR 621.16 | PKR 3.11/dose | Near median |
| NEUMOCORT FORTE METERD-DOSE INHALER | Budesonide | 400 mcg | Metered-dose inhaler | 100 doses | 059037 | PKR 311.46 | PKR 3.11/dose | Near median |
| NEUMOCORT METERD-DOSE INHALER | Budesonide | 200 mcg | Metered-dose inhaler | 200 doses | 059036 | PKR 391.48 | PKR 1.96/dose | Near median |
| NEUMOCORT METERD-DOSE INHALER | Budesonide | 200 mcg | Metered-dose inhaler | 100 doses | 059036 | PKR 195.73 | PKR 1.96/dose | Near median |
| Neutrofil | Filgrastim | 48 MU/1.6 mL | Injection | 1 Vial | 044837 | PKR 8,863.60 | PKR 8,863.60/vial/unit | No comparator |
| Neutrofil | Filgrastim (rHuG-CSF) | 48 MU | Injection | 1 Vial | 044837 | PKR 8,863.60 | PKR 8,863.60/vial/unit | No comparator |
| Oxitan | Oxaliplatin | 50 mg/10 mL (5 mg/mL) | Solution for infusion | 1 Vial | 110554 | PKR 14,126.70 | PKR 14,126.70/vial/unit | No comparator |
| Oxitan | Oxaliplatin | 100 mg/20 mL (5 mg/mL) | Solution for infusion | 1 Vial | 110555 | PKR 28,253.39 | PKR 28,253.39/vial/unit | No comparator |
| PABAL RTS | Carbetocin | 100 mcg/mL | Solution for IV/IM injection | 1's | 115734 | PKR 409.28 | PKR 409.28/vial/unit | No comparator |
| PABAL® RTS 100 MICROGRAMS FOR | Carbetocin | 100 MCG/mL | Injection | 5's | 115734 | PKR 1,964.53 | PKR 392.91/vial/unit | No comparator |
| PENTASA | MESALAZINE | 1 g | Sachet | 50's | 043091 | PKR 4,654.11 | PKR 93.08/sachet | No comparator |
| PENTASA | MESALAZINE | 1 g | Sachet | 7-Bottles | 044836 | PKR 4,044.02 | — | No comparator |
| VINELBINE | Vinorelbine tartrate | 10 mg | Injection | 1ml vial | 045751 | PKR 3,807.68 | PKR 3,807.68/mL | No comparator |
| Zexate | Methotrexate | 50 mg (25 mg/mL) | Injection | 1's | 047541 | PKR 360.08 | PKR 360.08/vial/unit | No comparator |
| Zexate | Methotrexate | 25 mg/mL (50 mg total) | Injection | 100's | 047541 | PKR 16,619.27 | PKR 166.19/vial/unit | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.